僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Cabiralizumab （FPA 008） is an anti-CSF1R monoclonal antibody （MAb）. Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis （RA）. Cabiralizumab can combine with Nivolumab （HY-P9903） for lung cancer research